Research Article
Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments
Table 4
Maximum acceptable risks.
| | Grade 3/4 adverse event | 6-month improvement in PFS from 10 months to 16 months (95% CI) | 8-month improvement in PFS from 10 months to 18 months (95% CI) |
| | Severe hand-foot skin reaction | 30.0% (21.5%–38.5%) | 38.5% (27.6%–49.3%) | | Severe proteinuria | 14.7% (10.0%–19.4%) | 18.8% (12.9%–24.8%) | | Severe hypertension | 16.5% (11.9%–21.0%) | 21.8% (16.0%–27.7%) |
|
|
CI = confidence interval; PFS = progression-free survival.
|
